MedTrace Logo

Study of Acitretin to Treat Skin Rash Caused by Erlotinib (a Chemotherapy Drug)

NCT01299220 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2013-01-16

No results posted yet for this study

Summary

This study will look at if a low-dose regimen of acitretin is helpful in treating a skin rash caused by the chemotherapy drug, erlotinib.

Conditions

  • Skin Rash

Interventions

DRUG

Acitretin

Acitretin 10 mg by mouth daily

Sponsors & Collaborators

  • OSI Pharmaceuticals

    collaborator INDUSTRY

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • Larisa J Geskin, MD · University of Pittsburgh Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01299220 on ClinicalTrials.gov